Epidemiological and clinical profile of immunosuppressed patients with imported strongyloidiasis: a substudy from a larger cohort of the +REDIVI Spanish Collaborative Network

Pathog Glob Health. 2021 Mar;115(2):121-124. doi: 10.1080/20477724.2020.1857491. Epub 2020 Dec 30.

Abstract

The aim of this study was to describe the clinical and epidemiological profile of immunosuppressed patients with imported strongyloidiasis in a non-endemic setting, and to compare these results with non-immunosuppressed patients. This is a case-control substudy from a larger observational retrospective study that included all patients with strongyloidiasis registered in the +REDIVI Spanish Collaborative Network. Overall, 1245 patients with imported strongyloidiasis were included. From these, 80 (6.4%) patients had some kind of immunosuppression. Three (3.8%) patients had a hyperinfection syndrome, and 34 (52.3%) patients had eosinophilia. The percentages of positive results of the formalin-ether technique, the fecal culture and serology were 12.3%, 21.1% and 95.4%, respectively. When comparing the main characteristics, immunosuppressed patients had higher proportion of severe clinical manifestations and lower proportion of eosinophilia. No differences were found regarding yield of microbiological techniques and treatment response. These results stress the importance of strongyloidiasis screening among immunosuppressed patients coming from endemic areas. Serological tests have an acceptable sensitivity to be used as a screening tool.

Keywords: HIV; Strongyloides stercoralis; immunosuppression; strongyloidiasis.

Publication types

  • Observational Study

MeSH terms

  • Animals
  • Case-Control Studies
  • Eosinophilia*
  • Humans
  • Immunocompromised Host*
  • Retrospective Studies
  • Strongyloides stercoralis
  • Strongyloidiasis* / diagnosis
  • Strongyloidiasis* / epidemiology

Grants and funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.